Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech Submits Warfarin Sensitivity Test to FDA

NEW YORK (GenomeWeb News) - Osmetech said today that it has submitted to the US Food and Drug Administration a test to identify patients who are at risk for sensitivity to the blood-thinner warfarin.
 
Osmetech said it conducted studies for the eSensor 2C9/VKOR test on its eSensor XT-8 tool at three evaluation sites, and that pre-clinical studies completed in November 2007 showed the test to be in agreement with results from bidirectional DNA sequencing.
 
In August, the FDA updated its label for warfarin to explain that an individual’s genetic makeup may influence response to a drug and may influence optimal dosing.
 
Osmetech’s CEO, James White, said the company is confident that it will receive clearance from the FDA for the test in the first half of this year.
 
The FDA in September cleared a test for warfarin sensitivity made by Nanosphere.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.